
Retinal degenerative diseases, such as glaucoma and age-related macular degeneration, cause irreversible vision loss. Gene therapy shows promise for treating these disorders, utilizing AAV vectors for efficient and targeted gene delivery into specific ocular cell types. AAV vectors offer safety, stable gene expression, and engineering flexibility. Considerations to choose the right AAV vector include cell type, administration route, and AAV variant. This overview explores AAV vectors for gene transfer into key ocular cell types, emphasizing their role in advancing retinal gene therapy in both research and (pre)clinical settings.
Like
Save
Share